Head-to-head evidence
CDNF (cerebral dopamine neurotrophic factor) vs HER-096
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: CDNF · full Parkinson's Disease pipeline
CDNF (cerebral dopamine neurotrophic factor)
Developed by Herantis Pharma Plc.
NCT03295786 · Phase 1/2 · completed
The study was randomized, quadruple-masked, and placebo-controlled, but it enrolled only 17 participants and was primarily designed to assess safety and clinical assessment measures rather than a definitive disease-outcome endpoint. Because no results are posted, it is not possible to determine whether any primary comparison was favorable.
HER-096
Developed by Herantis Pharma Plc.
NCT05915247 · Phase 1 · completed
The trial randomized subjects against placebo with full blinding in Part 1, a solid safety-study design, but it measured only safety and drug levels rather than a disease outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CDNF (cerebral dopamine neurotrophic factor)'s landscape · HER-096's landscape